Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 34 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

21%

7 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (10)
P 1 (2)
P 2 (6)
P 3 (2)
P 4 (5)

Trial Status

Unknown9
Recruiting8
Completed7
Not Yet Recruiting6
Withdrawn2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT07557810Recruiting

Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism

NCT07362693Recruiting

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

NCT07256522Not ApplicableRecruiting

Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger

NCT07053137Active Not Recruiting

A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.

NCT06732427Not ApplicableRecruitingPrimary

Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment

NCT06690424Phase 4RecruitingPrimary

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

NCT07126639Not ApplicableNot Yet RecruitingPrimary

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

NCT07061184Phase 4Not Yet Recruiting

Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial

NCT06914661Enrolling By Invitation

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06818097Completed

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06826885Recruiting

Safety and Efficacy of IMPT or IMRT for Breast Cancer

NCT06194188Phase 2CompletedPrimary

A Phase 2 Clinical Study of CU-20401

NCT03901235Phase 1RecruitingPrimary

MSC Intratissular Injection in Crohn Disease Patients

NCT03623776Phase 2WithdrawnPrimary

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

NCT04518501Phase 1RecruitingPrimary

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

NCT06709586Not Yet Recruiting

Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism

NCT06708871Not Yet Recruiting

Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism

NCT06351735Not Yet RecruitingPrimary

Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis

NCT06383078Phase 2Not Yet RecruitingPrimary

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

NCT06218004Phase 2UnknownPrimary

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Scroll to load more

Research Network

Activity Timeline